Muvalaplin clinical trials
Also written LY3473329.
ClinicalTrials.gov finds 1 studies for muvalaplin. How that becomes 6 here
Every study that search finds has been read, to see whether and how it gives muvalaplin. ClinicalTrials.gov counts as of Nov 11, 2026. How drug pages count
- 1Found by its intervention search · See all 1 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 1 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- +5Give it under a name that search misses: a biosimilar’s code or a misspelling
- 6Give muvalaplin to participants
- 6Test it: the count on this site
Get an email when these change. Save the muvalaplin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses muvalaplin has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 6
- Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)RecruitingPhase 3Eli Lilly and CompanyNCT07157774On major cardiovascular events in high Lp(a)Written as MuvalaplinReport a problem
- A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular EventsCompletedPhase 2Eli Lilly and CompanyNCT05563246Dose finding in high Lp(a) at high cardiovascular risk (KRAKEN)Written as LY3473329Report a problem
- A Study of LY3473329 in Participants With Impaired and Normal Renal FunctionCompletedPhase 1Eli Lilly and CompanyNCT05778864In renal impairmentWritten as LY3473329Report a problem
- A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06342596Mass balance with carbon-14 labelWritten as [14C]-LY3473329Report a problem
- A Study of LY3473329 in Healthy Japanese ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05038787In healthy Japanese participantsWritten as LY3473329Report a problem
- A Study of LY3473329 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04472676First in human, in healthy participantsWritten as LY3473329Report a problem
Tested on its own · 6 — no other medicine in its arm
- Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)RecruitingPhase 3Eli Lilly and CompanyNCT07157774On major cardiovascular events in high Lp(a)Written as MuvalaplinReport a problem
- A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular EventsCompletedPhase 2Eli Lilly and CompanyNCT05563246Dose finding in high Lp(a) at high cardiovascular risk (KRAKEN)Written as LY3473329Report a problem
- A Study of LY3473329 in Participants With Impaired and Normal Renal FunctionCompletedPhase 1Eli Lilly and CompanyNCT05778864In renal impairmentWritten as LY3473329Report a problem
- A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06342596Mass balance with carbon-14 labelWritten as [14C]-LY3473329Report a problem
- A Study of LY3473329 in Healthy Japanese ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05038787In healthy Japanese participantsWritten as LY3473329Report a problem
- A Study of LY3473329 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04472676First in human, in healthy participantsWritten as LY3473329Report a problem
Codes
What other systems call muvalaplin · ClinicalTrials.gg INT016800
- UNII (FDA) HSU2KY4EFKMUVALAPLINOne source FDA
- NCI Thesaurus C190757MuvalaplinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | HSU2KY4EFK | MUVALAPLIN | One source FDA |
| NCI Thesaurus | C190757 | Muvalaplin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.